Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) shares rose 2.5% during mid-day trading on Wednesday . The stock traded as high as $14.79 and last traded at $14.60, with a volume of 114,968 shares trading hands. The stock had previously closed at $14.24.

ADMS has been the subject of several recent analyst reports. Noble Financial restated a “buy” rating and set a $25.00 target price on shares of Adamas Pharmaceuticals in a research report on Friday, July 22nd. Needham & Company LLC restated a “buy” rating and set a $38.00 target price on shares of Adamas Pharmaceuticals in a research report on Wednesday, July 20th. JMP Securities initiated coverage on Adamas Pharmaceuticals in a research report on Friday, April 1st. They set an “outperform” rating and a $29.00 target price for the company. Mizuho boosted their target price on Adamas Pharmaceuticals from $14.00 to $17.00 and gave the company a “neutral” rating in a research report on Thursday, April 28th. Finally, Credit Suisse Group AG restated a “buy” rating and set a $21.00 target price on shares of Adamas Pharmaceuticals in a research report on Monday. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $32.00.

The firm’s market capitalization is $315.75 million. The company has a 50-day moving average price of $15.90 and a 200 day moving average price of $16.19.

Adamas Pharmaceuticals (NASDAQ:ADMS) last released its quarterly earnings data on Tuesday, May 10th. The specialty pharmaceutical company reported ($0.65) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.76) by $0.11. On average, analysts forecast that Adamas Pharmaceuticals Inc. will post ($3.09) EPS for the current fiscal year.

A hedge fund recently raised its stake in Adamas Pharmaceuticals stock. Dimensional Fund Advisors LP raised its position in shares of Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) by 585.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 69,411 shares of the specialty pharmaceutical company’s stock after buying an additional 59,285 shares during the period. Dimensional Fund Advisors LP owned approximately 0.38% of Adamas Pharmaceuticals worth $1,966,000 at the end of the most recent quarter.

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is focused on the development and commercialization of therapeutics targeting chronic disorders of the central nervous systems (CNS). Its segment focuses on the development and commercialization of therapeutics targeting chronic disorders of the central nervous system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.